| (Values in U.S. Thousands) | Mar, 2023 | Mar, 2022 | Mar, 2021 | Feb, 2026 | Feb, 2026 |
| Sales | 100,000 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -21,170 | 7,130 | -550 | 0 | 0 |
| Net Income Growth | -396.91% | +1,396.36% | unch | unch | unch |
Ys Biopharma Co. Ltd (YS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
YS Biopharma Co. Ltd. is a biopharmaceutical company. It focuses on discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company operates principally in China, the United States, Singapore, the United Arab Emirates and the Philippines. YS Biopharma Co. Ltd., formerly known as Summit Healthcare Acquisition Corp., is based in NEW YORK.